OncoMatch/Clinical Trials/NCT05669820
Antisecretory Factor Glioblastoma Phase 2
Is NCT05669820 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies non-drug interventions for glioblastoma.
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Demographics
Prior therapy
Must have received: surgical resection
Surgical treatment-resection.
Cannot have received: surgical biopsy only
Only surgical biopsy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05669820 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgical biopsy only disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages